

ASX Announcement | 1 July 2019
Visioneering Technologies (ASX:VTI)

Completion of Rights Offering

Atlanta, Georgia, USA 1 July 2019: US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses **Visioneering Technologies, Inc (ASX: VTI), (Visioneering or Company)**, announces the completion of its fully underwritten non-renounceable rights offering to raise approximately A\$5.8 million (**Rights Offering**), which opened on 17 June 2019.

Under the Rights Offering, eligible holders of CHES Depository Interests (**CDIs**) and shares were invited to subscribe for 9 new CDIs for every 19 CDIs or shares in the Company of which they were the registered holder at 7.00pm (AEST) on 12 June 2019 at an issue price of A\$0.045 per CDI. The Rights Offering closed on 26 June 2019.

In accordance with the ASX Listing Rules, the Company advises that it has accepted valid applications under the Rights Offering for 45,887,740 new CDIs in the Company (**New CDIs**) (to raise approximately A\$2.1 million).

The balance of 82,405,896 New CDIs, being CDIs not subscribed for by eligible securityholders, will be issued to the underwriter and the sub-underwriter in accordance with the underwriting and the sub-underwriting arrangements described in the Offer Booklet.

The Rights Offering will raise approximately A\$5.8 million before costs and expenses.

New CDIs are expected to be issued on Thursday, 4 July 2019 and are expected to commence trading on a normal settlement basis on ASX on Friday, 5 July 2019.

For more information, please contact:

Visioneering Technologies

Stephen Snowdy

CEO

E: ssnowdy@vtivision.com

Investor & Media Relations

Julia Maguire

The Capital Network

M: +61 419 815 386

E: julia@thecapitalnetwork.com.au

About Visioneering Technologies

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. Since its founding in 2008, Visioneering has brought together clinical, marketing, engineering, manufacturing and regulatory leaders from top vision care businesses to provide new solutions for presbyopia, myopia and astigmatism.

Headquartered in the US, Visioneering designs, manufactures, sells and distributes contact lenses. Its flagship product is the NaturalVue® Multifocal contact lens, and VTI has expanded its portfolio of

technologies to address a range of eye care issues. The company has grown operations across the United States, Australia and Europe and is expanding into Asia with a focus on markets with high rates of myopia.

Foreign Ownership Restrictions

VTI's CHES Depository Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product as well as our expectations with respect to our ability to develop and commercialize new products.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX92